NanoOncology is a biotechnology company that was recently purchased by PeptiMed. Its mission is to identify specific tumor-causing genetic targets and designing small interfering RNA (siRNA)-based drugs and small molecules drugs that inhibit the tumor promoting function of gene products for each patient on an individual basis. The company invented EVIRNA ™, a proprietary siRNA therapeutic drug that targets the EVI1 gene for treatment of advanced breast, prostate, lung, colon, ovarian, and skin cancer. NanoOncology also invented a unique polypeptide-based nanoparticle system for delivery of siRNA directly to tumor cells.